Navigation Links
Activplant Corporation Announces Global Agreement with GlaxoSmithKline
Date:2/10/2009

Industry Leaders Team up to Drive Performance Improvements World Wide

LONDON, Ontario, Feb. 10 /PRNewswire/ -- Activplant Corporation (www.activplant.com) announced today that GlaxoSmithKline PLC (GSK) has signed a global framework agreement naming Activplant as a recommended business intelligence solution for their world wide manufacturing sites.

The agreement comes after a successful implementation where GSK experienced the ease of use that empowers operators, engineers and management to positively affect their OEE, and consequently, their production costs. Activplant's Throughput Analyzer software product is currently implemented within key GSK facilities in North America and the UK.

"Once we saw how quickly Activplant's Throughput Analyzer could be implemented and drive results in our facility in North Carolina, we felt that it made sense to negotiate a global framework agreement to reduce complexity where our facilities wish to consider implementing OEE projects," said Julian Ward, GSK's application champion. "Over the next 3 months our aim is to achieve a 5% improvement in OEE on the lines running Throughput Analyzer and, with what we have seen to date, we feel we'll improve throughput and efficiencies across all lines where we implement the solution."

"Today's global manufacturing landscape is becoming increasingly competitive and complex. It is critical for manufacturers to arm themselves with real-time operations intelligence facilitating improved decision making and driving a reduction in operating costs," states Activplant President, Drew Forret. "We are thrilled to add GSK as a valued business partner. They are a recognized leader in the Pharmaceutical and Consumer Healthcare sectors, both of which have played an important role in Activplant's continued growth strategy."

Activplant Corporation- an enterprise manufacturing intelligence market leader, Activplant's solutions have set the standard in operational excellence within the world's largest and most admired manufacturers. Aimed at high-volume, high-automation plants, Activplant's technology consolidates plant floor data into relevant real-time and historical intelligence, enabling productivity gains through better decision making. With Activplant solutions, manufacturers can focus on the key issues in their facilities and thereby improve throughput, product quality, and operating margins. Activplant is a privately held company based in London, Ontario. For more information please visit www.activplant.com .

GlaxoSmithKline- one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com


'/>"/>
SOURCE Activplant Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... Doctor C LLC, a company based out of Arizona that ... continue the marketing and distribution of its product, The Right C. , The Right ... absorption than traditional vitamin C supplements. At the trade show, Doctor C had the ...
(Date:1/20/2017)... ... , ... International Protein, a company based out of Australia that focuses on ... ECRM trade show in Hilton Head, SC. , International Protein was founded by ... line of products that would elevate her fitness regime. At this ECRM trade show, ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Mary Magdalene: Grace ... mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is ... who spent her career as an educator interacting with countless women who had little ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study ... Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Land ... brings attention to the issue of world hunger, and shares the simple and achievable ... Brubaker, devoted husband and member of the Fairview Missionary Church in Angola, Indiana where ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food and ... Chronic Idiopathic Constipation (CIC) in adult patients. ... gastrointestinal disorders," said Julie Beitz , M.D., director of ... for Drug Evaluation and Research. "With the availability of new ... treatment for their condition." ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
Breaking Medicine Technology: